# Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization

> **NCT02726074** · PHASE4 · COMPLETED · sponsor: **Eisai Korea Inc.** · enrollment: 106 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Perampanel

## Key facts

- **NCT ID:** NCT02726074
- **Lead sponsor:** Eisai Korea Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-03
- **Primary completion:** 2018-04-26
- **Final completion:** 2018-04-26
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02726074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02726074, "Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02726074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*